Tuesday, August 19, 2025 8/19/2025

Advancing Equitable Risk-based Breast Cancer Screening and Surveillance in Community Practice

Award Number: P01CA154292
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/27/2011
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

Advancing Equitable Risk-based Breast Cancer Screening and Surveillance in Community Practice - Breast cancer remains the second leading cause of cancer death in United States women, with racial and ethnic disparities in breast cancer stage at diagnosis, rates of second breast cancers, and mortality. Our Program renewal follows the premise that screening and surveillance will be most effective and equitable when all women have access to high-quality risk assessment and breast imaging, and when screening and surveillance strategies are targeted to clinically meaningful outcomes. Our current Program has advanced the science of risk-based screening and surveillance by: (1) identifying clinical risk factors most predictive of invasive breast cancer for the general population and for racial and ethnic groups; (2) defining and evaluating advanced cancer as a screening outcome; (3) assessing new screening technologies and their use in underserved populations; (4) identifying multilevel factors that influence women’s views of risk-based screening; and (5) identifying breast cancer survivors at high risk of an interval second breast cancer. During the next funding period, we propose three complementary Projects supported by three Cores. Project 1 aims to develop equitable advanced breast cancer risk models that incorporate imaging features, artificial intelligence (AI) algorithms, and clinical factors; and compare the benefits and harms of targeted screening frequency and supplemental MRI based on advanced cancer risk. Project 2 takes a multilevel approach to identify woman-, neighborhood-, and facility-level factors that drive inequities in breast cancer screening performance and outcomes, and to explore whether targeted AI use and other interventions can improve population outcomes with attention to health equity. Project 3 focuses on improving surveillance imaging in breast cancer survivors through equitably predicting women at high risk of a surveillance failure (i.e., interval 2nd breast cancer), improving surveillance performance through AI, and examining social determinants of health as multilevel drivers of surveillance failures and targets for future interventions. The Administrative Core will provide overall scientific leadership and administration for an integrated Program. The Biostatistics and Data Management Core will provide centralized coordination of high-quality data collection, management, analysis, and sharing. The Comparative Effectiveness Core will provide specialized multidisciplinary expertise in decision sciences, risk communication, and qualitative research along with three established Cancer Intervention and Surveillance Modeling Network (CISNET) modeling groups to support the clinical and policy translation of Program findings. The Program leverages the Breast Cancer Surveillance Consortium, an established research network with robust, community-based, prospective data collection from geographically and socio-demographically diverse settings. Program findings will play a critical role in public health efforts to promote equitable, risk-based screening and surveillance and reduce breast cancer disparities.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $2,805,350 )
2024	2024	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	002	13	9/11/2024	SUPPLEMENT FOR EXPANSION	$209,440
2024	2024	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	000	12	7/30/2024	SUPPLEMENT FOR EXPANSION	$117,898
2024	2024	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	001	13	9/3/2024	NON-COMPETING CONTINUATION	$2,478,012
														Subtotal = $2,805,350

Issue Date FY: 2023 ( Subtotal = $2,928,797 )
2023	2023	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	005	12	9/22/2023	NON-COMPETING CONTINUATION	$58,575
2023	2023	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	004	12	8/10/2023	NON-COMPETING CONTINUATION	$2,870,222
2023	2022	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	000	11	12/12/2022	COMPETING CONTINUATION	$0
2023	2022	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	001	11	3/7/2023	COMPETING CONTINUATION	$0
2023	2022	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	003	11	6/15/2023	COMPETING CONTINUATION	$93,831
2023	2021	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	002	10	6/15/2023	NON-COMPETING CONTINUATION	-$93,831
														Subtotal = $2,928,797

Issue Date FY: 2022 ( Subtotal = $3,818,184 )
2022	2022	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	001	11	9/16/2022	COMPETING CONTINUATION	$3,818,184
2022	2021	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	000	10	9/12/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $3,818,184

Issue Date FY: 2021 ( Subtotal = $3,379,703 )
2021	2021	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	002	10	6/4/2021	NON-COMPETING CONTINUATION	$3,379,703
2021	2015	KAISER FOUNDATION HEALTH PLAN OF WASHINGTON	601 UNION ST STE 3100	SEATTLE	WA	98101	KING	USA	Cancer Cause and Prevention Research	000	5	10/1/2020	NON-COMPETING CONTINUATION	-$105,103
2021	2015	KAISER FOUNDATION HEALTH PLAN OF WASHINGTON	601 UNION ST STE 3100	SEATTLE	WA	98101	KING	USA	Cancer Cause and Prevention Research	001	5	10/3/2020	NON-COMPETING CONTINUATION	$105,103
														Subtotal = $3,379,703

Issue Date FY: 2020 ( Subtotal = $3,698,425 )
2020	2020	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	001	9	7/27/2020	SUPPLEMENT FOR EXPANSION	$149,977
2020	2020	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	000	9	5/21/2020	NON-COMPETING CONTINUATION	$3,548,448
														Subtotal = $3,698,425

Issue Date FY: 2019 ( Subtotal = $3,238,201 )
2019	2019	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	000	8	7/24/2019	NON-COMPETING CONTINUATION	$3,238,201
														Subtotal = $3,238,201

Issue Date FY: 2018 ( Subtotal = $3,675,469 )
2018	2018	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	004	7	9/25/2018	NON-COMPETING CONTINUATION	-$200,000
2018	2018	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Trans-NIH Research Support	005	7	9/26/2018	SUPPLEMENT FOR EXPANSION	$200,000
2018	2018	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	002	7	5/25/2018	NON-COMPETING CONTINUATION	$3,475,469
2018	2018	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	003	7	9/5/2018	NON-COMPETING CONTINUATION	$200,000
2018	2017	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	001	6	12/1/2017	COMPETING CONTINUATION	$12,346
2018	2015	KAISER FOUNDATION HEALTH PLAN OF WASHINGTON	601 UNION ST STE 3100	SEATTLE	WA	98101	KING	USA	Cancer Cause and Prevention Research	000	5	12/1/2017	NON-COMPETING CONTINUATION	-$12,346
														Subtotal = $3,675,469

Issue Date FY: 2017 ( Subtotal = $3,500,336 )
2017	2017	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	002	6	7/21/2017	COMPETING CONTINUATION	$28,368
2017	2017	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Cancer Cause and Prevention Research	001	6	6/30/2017	COMPETING CONTINUATION	$3,471,968
2017	2015	KAISER FOUNDATION HEALTH PLAN OF WASHINGTON	600 UNIVERSITY ST STE 3100	SEATTLE	WA	98101	KING	USA	Cancer Cause and Prevention Research	000	5	6/30/2017	NON-COMPETING CONTINUATION	$0
														Subtotal = $3,500,336

Issue Date FY: 2015 ( Subtotal = $3,643,635 )
2015	2015	GROUP HEALTH COOPERATIVE CENTRAL HOSPITAL	201 16TH AVENUE, EAST	SEATTLE	WA	98112	KING	USA	Cancer Cause and Prevention Research	000	5	8/27/2015	NON-COMPETING CONTINUATION	$3,643,635
														Subtotal = $3,643,635

Issue Date FY: 2014 ( Subtotal = $3,657,805 )
2014	2014	GROUP HEALTH COOPERATIVE CENTRAL HOSPITAL	201 16TH AVENUE, EAST	SEATTLE	WA	98112	KING	USA	Cancer Cause and Prevention Research	000	4	9/4/2014	NON-COMPETING CONTINUATION	$3,657,805
														Subtotal = $3,657,805

Issue Date FY: 2013 ( Subtotal = $3,675,407 )
2013	2013	GROUP HEALTH COOPERATIVE CENTRAL HOSPITAL	201 16TH AVENUE, EAST	SEATTLE	WA	98112	KING	USA	Cancer Cause and Prevention Research	000	3	9/12/2013	NON-COMPETING CONTINUATION	$3,675,407
														Subtotal = $3,675,407

Issue Date FY: 2012 ( Subtotal = $4,025,994 )
2012	2012	GROUP HEALTH COOPERATIVE CENTRAL HOSPITAL	201 16TH AVENUE, EAST	SEATTLE	WA	98112	KING	USA	Cancer Cause and Prevention Research	000	2	9/10/2012	NON-COMPETING CONTINUATION	$4,025,994
														Subtotal = $4,025,994

Issue Date FY: 2011 ( Subtotal = $3,988,949 )
2011	2011	GROUP HEALTH COOPERATIVE CENTRAL HOSPITAL	201 16TH AVENUE, EAST	SEATTLE	WA	98112	KING	USA	Cancer Cause and Prevention Research	000	1	9/26/2011	NEW	$3,988,949
														Subtotal = $3,988,949

Grand Total All Awards = $46,036,255

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Advancing Equitable Risk-based Breast Cancer Screening and Surveillance in Community Practice

Award Number: P01CA154292

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/27/2011

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer